Evaluating quality of life after surgery for rectal cancer
Official title: Prospective Evaluation of Quality of Life and Utilities Following Surgical Treatment of Rectal Cancer
Run by M.D. Anderson Cancer Center · NCT02107105 · Data updated 2026-11-12
This study looks at how surgery for rectal cancer affects the quality of life for patients over time, comparing those who received radiation therapy to those who didn’t.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 430 (estimated) |
| Sponsor | M.D. Anderson Cancer Center Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Houston, Texas) |
| Status | Recruiting |
| Started | May 16, 2014 |
| Main results expected | May 31, 2030 |
| Study ends | May 31, 2030 |
| Registry record updated | August 31, 2026 |
| Trial ID | NCT02107105 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include patients with histologically confirmed adenocarcinoma of the rectum at stages I-IV who are undergoing or have undergone surgical resection.
✕Probably not a fit
Patients with concurrent cancer diagnoses, recurrent disease, or those treated with pelvic radiation for other cancers may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study assesses the quality of life and health state utilities in patients who have undergone surgical treatment for stage I-IV rectal cancer. Patients will complete quality of life questionnaires at various intervals, including baseline, 6 months, 12 months, and annually up to 5 years post-surgery. The study aims to compare the effects of treatment with or without (neo)adjuvant radiation therapy and to track changes in quality of life over time.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into the long-term quality of life for rectal cancer patients post-surgery.
How similar studies have gone: Other studies have successfully evaluated quality of life in cancer patients, suggesting that this approach is both relevant and valuable.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient has histologically proven adenocarcinoma of the rectum (stage I - IV) that is planned to be treated by surgical resection performed with curative intent, or who has already received surgical treatment * Patient must sign an approved informed consent document and have the literary and physical ability to complete the questionnaire in English Exclusion Criteria: * Patient has been treated with pelvic radiation therapy for a diagnosis other than rectal cancer * Patient has a concurrent cancer diagnosis at the time of consent * Patient has recurrent disease
Where it's running
-
M D Anderson Cancer Center
Houston, Texas, United States Recruiting
Study contacts
- Principal investigator: George J Chang — M.D. Anderson Cancer Center
- Study coordinator: George Chang
- Email: GChang@mdanderson.org
- Phone: 713-792-6940
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Using blood tests to improve treatment strategies for rectal cancer
This study is testing if measuring tumor DNA in the blood can help doctors see how well treatments are working for people with stage II-III rectal cancer.
-
Short course radiation therapy combined with chemotherapy for stage II-III rectal cancer
This study is testing a new treatment plan that combines short radiation therapy with chemotherapy to see if it helps people with stage II-III rectal cancer feel better and have fewer problems after treatment.
-
Monitoring and chemotherapy before surgery for stage II-III rectal cancer
This study tests if monitoring and chemotherapy before surgery can help people with stage II-III rectal cancer keep their organs and improve their treatment choices.
-
Neoadjuvant Botensilimab and Balstilimab for Advanced Resectable Colorectal Cancer
This phase 2 trial tests whether giving botensilimab and balstilimab before surgery can help patients with advanced, resectable colorectal cancer see better outcomes.
-
Family genetics: who shares test results with relatives
This study tests whether letting patients share genetic results with their relatives is as good as doctors sharing the results to help first-degree relatives get genetic testing for hereditary cancer risk.
-
Zanidatamab given before surgery for HER2-positive colon or rectal cancer
This tests whether giving zanidatamab before surgery helps adults with HER2-positive, RAS‑wildtype colon or rectal cancer who are planned for curative treatment.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.